|
 Hello Immunization Partners,
Please share this information with staff and colleagues.
On September 6, 2024, the Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States was updated to include the use of 2024-25 Novavax COVID-19 Vaccine in individuals 12 years of age and older. This vaccine includes a monovalent (single) component that corresponds to the Omicron variant JN.1 strain of SARS-CoV-2 versus the KP.2 strain found in the 2024-25 Moderna and Pfizer-BioNTech vaccines. The 2023-2024 Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines are no longer recommended and should not be used. There is no preferential recommendation for the use of any one COVID-19 vaccine over another when more than one recommended and age-appropriate vaccine is available.
Authorized use of 2024-2025 Novavax COVID-19 Vaccine in individuals 12 years of age and older is as follows:
- Individuals who have never been vaccinated with any COVID-19 vaccine:
- 2 doses of 2024-25 Novavax vaccine are administered 3 weeks apart
- Individuals who have been vaccinated with only one dose of any Novavax COVID-19 vaccine:
- 1 dose of 2024-25 Novavax vaccine is administered at least 3 weeks after receipt of the previous dose
- Individuals who have been vaccinated with a prior formula of a COVID-19 vaccine from another manufacturer or with two or more doses of a prior formula of Novavax vaccine:
- 1 dose of 2024-25 Novavax vaccine at least 2 months after the last dose of the COVID-19 vaccine
- Immunocompromised individuals:
- An additional dose of 2024-25 Novavax vaccine may be administered at least 2 months following the last dose of a 2024-25 COVID-19 vaccine
- Additional doses of 2024-25 Novavax vaccine may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances. Timing of the additional doses may be based on the individual's clinical circumstances.
Interchangeability of COVID-19 Vaccines:
- People ages 12 years and older who are initiating vaccination with Novavax vaccine (i.e., previously unvaccinated) and receive a first dose of Novavax should complete the 2-dose initial vaccination series with Novavax vaccine. However, if more than 8 weeks have elapsed since receipt of the first dose of Novavax, any 2024-25 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) may be administered.
- See Appendix B for additional information if doses from different manufacturers are administered for initial vaccination.
Michigan version of Novavax EUA information:
Thank you for all your hard work.
Oakland County Health Division, Immunization Action Plan
|
|
|
|
